DK2510942T3 - Anvendelse af natriuretiske peptider til behandling af hjertesvigt - Google Patents
Anvendelse af natriuretiske peptider til behandling af hjertesvigt Download PDFInfo
- Publication number
- DK2510942T3 DK2510942T3 DK12156696.2T DK12156696T DK2510942T3 DK 2510942 T3 DK2510942 T3 DK 2510942T3 DK 12156696 T DK12156696 T DK 12156696T DK 2510942 T3 DK2510942 T3 DK 2510942T3
- Authority
- DK
- Denmark
- Prior art keywords
- ularitide
- hours
- patients
- placebo
- groups
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (4)
1. Urodilatin til anvendelse ved behandling af akut dekompenseret hjertesvigt, hvor urodilatin indgives kontinuert i et tidsrum på mindst 24 timer.
2. Urodilatin ifølge krav 1, hvor urodilatin er egnet til intravenøs indgivelse.
3. Urodilatin ifølge krav 2, hvor urodilatin er egnet til indgivelse med en hastighed på mindst 7,5 ng/(kg min); eller med en hastighed på 7,5 ng/(kg min); eller med en hastighed på 15 ng/(kg min); eller med en hastighed på 30 ng/(kg min); eller med en hastighed på 45 ng/(kg min); eller med en hastighed på 60 ng/(kg min); eller med en hastighed på 100 ng/(kg min); eller med en hastighed på 200 ng/(kg min).
4. Urodilatin ifølge krav 2, hvor urodilatin yderligere omfatter et farmaceutisk acceptabelt excipiens eller bærestof.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66978605P | 2005-04-07 | 2005-04-07 | |
US66975105P | 2005-04-08 | 2005-04-08 | |
US73258505P | 2005-11-01 | 2005-11-01 | |
EP06749753A EP1865976B1 (en) | 2005-04-07 | 2006-04-07 | Use of natriuretic peptide for treating heart failure |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2510942T3 true DK2510942T3 (da) | 2015-12-14 |
Family
ID=37087353
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12156696.2T DK2510942T3 (da) | 2005-04-07 | 2006-04-07 | Anvendelse af natriuretiske peptider til behandling af hjertesvigt |
DK06749753.7T DK1865976T3 (da) | 2005-04-07 | 2006-04-07 | Anvendelse af natriuretiske peptider til behandling af hjertesvigt |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06749753.7T DK1865976T3 (da) | 2005-04-07 | 2006-04-07 | Anvendelse af natriuretiske peptider til behandling af hjertesvigt |
Country Status (10)
Country | Link |
---|---|
US (5) | US7732406B2 (da) |
EP (2) | EP2510942B1 (da) |
CY (1) | CY1113183T1 (da) |
DK (2) | DK2510942T3 (da) |
ES (2) | ES2392892T3 (da) |
HU (1) | HUE026231T2 (da) |
PL (2) | PL2510942T3 (da) |
PT (2) | PT2510942E (da) |
SI (1) | SI2510942T1 (da) |
WO (1) | WO2006110743A1 (da) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2365023T3 (es) | 2004-04-21 | 2011-09-20 | Enobia Pharma Inc. | Conjugados de administración ósea y método de uso de los mismos para dirigir proteínas a hueso. |
PL2510942T3 (pl) | 2005-04-07 | 2016-02-29 | Cardiorentis Ag | Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca |
US7606617B2 (en) * | 2006-01-31 | 2009-10-20 | Cardiac Pacemakers, Inc. | Urinalysis for the early detection of and recovery from worsening heart failure |
US20080181903A1 (en) * | 2006-12-21 | 2008-07-31 | Pdl Biopharma, Inc. | Conjugate of natriuretic peptide and antibody constant region |
CN101541957B (zh) | 2007-07-20 | 2013-08-14 | 梅约医学教育与研究基金会 | 利尿钠多肽 |
EP2078530A1 (en) * | 2008-01-08 | 2009-07-15 | Pharis Biotec GmbH | Use of natriuretic peptides for treating angioedema syndromes |
EP2185183B1 (en) | 2007-09-11 | 2016-03-16 | Cardiopep Pharma GmbH | Use of natriuretic peptides for treating angioedema syndromes |
WO2010033207A1 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
US20130197188A1 (en) * | 2010-03-15 | 2013-08-01 | Wolf-Georg Forssmann | Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound |
JP6055779B2 (ja) | 2010-12-27 | 2016-12-27 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | ナトリウム利尿ペプチドを含む組成物およびその使用方法 |
US20120277155A1 (en) * | 2011-02-25 | 2012-11-01 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure |
US20150038418A1 (en) * | 2011-07-27 | 2015-02-05 | Medtronic, Inc. | Natriuretic peptide compositions and methods of preparation |
US9102707B2 (en) | 2011-08-30 | 2015-08-11 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides |
US20130244937A1 (en) | 2011-09-02 | 2013-09-19 | Nile Therapeutics, Inc. | Chimeric natriuretic peptide compositions and methods of preparation |
US9611305B2 (en) | 2012-01-06 | 2017-04-04 | Mayo Foundation For Medical Education And Research | Treating cardiovascular or renal diseases |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
TW201442722A (zh) * | 2013-01-25 | 2014-11-16 | Cardiorentis Ltd | 肽於治療心血管適應症之用途 |
WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
US10449236B2 (en) | 2014-12-05 | 2019-10-22 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
AU2016211447B2 (en) | 2015-01-28 | 2021-09-23 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
EP3337894A1 (en) | 2015-08-17 | 2018-06-27 | Alexion Pharmaceuticals, Inc. | Manufacturing of alkaline phosphatases |
WO2017058822A1 (en) | 2015-09-28 | 2017-04-06 | Alexion Pharmaceuticals, Inc. | Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia |
EP3368062A4 (en) | 2015-10-30 | 2019-07-03 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT |
EP3426286A4 (en) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING HYPOPHOSPHATASE IN CHILDREN |
JP2019513711A (ja) | 2016-04-01 | 2019-05-30 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
EP3464573A4 (en) | 2016-06-06 | 2020-02-19 | Alexion Pharmaceuticals, Inc. | IMPACT OF METAL ON THE PRODUCTION OF ALKALINE PHOSPHATASES |
US11116821B2 (en) | 2016-08-18 | 2021-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
KR20190129058A (ko) | 2017-03-31 | 2019-11-19 | 알렉시온 파마슈티칼스, 인코포레이티드 | 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법 |
CN109838289B (zh) * | 2017-11-27 | 2022-03-15 | 罗伯特·博世有限公司 | 尿素水溶液喷射系统的回抽过程监测系统和方法 |
WO2019190752A1 (en) | 2018-03-30 | 2019-10-03 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
EP4117692A4 (en) * | 2020-03-13 | 2024-05-01 | Mayo Foundation for Medical Education and Research | ASSESSMENT AND TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE |
WO2022029499A1 (en) * | 2020-08-06 | 2022-02-10 | Ads Aiphia Development Services Ag | Methods of treating refractory ascites |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3346953A1 (de) | 1983-12-24 | 1985-08-14 | Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg | Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung |
US5449751A (en) * | 1987-03-02 | 1995-09-12 | Pharma Bissendorf Peptide Gmbh | Cardiodilatin fragment, process for preparing same and use thereof |
JP2819467B2 (ja) | 1987-03-02 | 1998-10-30 | ファーマ・ビッセンドルフ・ペプタイド・ゲーエムベーハー | 新規なカルジオジラチン断片およびその製造方法 |
US5461142A (en) * | 1987-11-07 | 1995-10-24 | Pharma Bissendorf Peptide Gmbh | Phosphorylated derivatives of cardiodilatin/ANF peptides |
US5166191A (en) | 1991-08-19 | 1992-11-24 | Genentech, Inc. | Use of relaxin in cardiovascular therapy |
DE4216133A1 (de) * | 1992-05-15 | 1993-11-18 | Bissendorf Peptide Gmbh | Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen |
US5514670A (en) * | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
ATE226960T1 (de) * | 1994-06-02 | 2002-11-15 | Forssmann Wolf Georg | Verfahren zur herstellung von cardiodilatin- fragmenten, hochgereinigte cardiodilatin- fragmente und zwischenprodukte zu deren herstellung |
US5741776A (en) | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
AU6820898A (en) | 1997-04-04 | 1998-10-30 | Novo Nordisk A/S | Natriuretic peptide derivatives |
DE19951471A1 (de) | 1999-10-26 | 2001-05-03 | Forssmann Wolf Georg | Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen |
US6831084B1 (en) | 1999-11-12 | 2004-12-14 | Wyeth | Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-HT1A activity |
US6407211B1 (en) | 1999-12-17 | 2002-06-18 | Mayo Foundation For Medical Education And Research | Chimeric natriuretic peptides |
WO2002028418A1 (en) | 2000-10-04 | 2002-04-11 | Molecular Medicine Research Institute | Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
KR101271635B1 (ko) | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
US20050113286A1 (en) | 2002-03-18 | 2005-05-26 | Schreiner George F. | Methods for treating congestive heart failure |
EP1490683A2 (en) | 2002-03-18 | 2004-12-29 | Scios Inc. | Treatment of congestive heart failure with natriuretic peptide and a diuretic |
CA2504287A1 (en) * | 2002-11-26 | 2004-06-10 | Nobex Corporation | Natriuretic compounds, conjugates, and uses thereof |
US20060008415A1 (en) | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
US8067464B2 (en) | 2004-10-04 | 2011-11-29 | Nitromed, Inc. | Compositions and methods using apocynin compounds and nitric oxide donors |
WO2006091716A2 (en) | 2005-02-24 | 2006-08-31 | Nitromed, Inc. | Nitric oxide enhancing diuretic compounds, compositions and methods of use |
PL2510942T3 (pl) | 2005-04-07 | 2016-02-29 | Cardiorentis Ag | Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca |
US20100168011A1 (en) | 2006-12-12 | 2010-07-01 | Amylin Pharmaceuticals, Inc. | Pharmaceutical Formulations and Methods for Making the Same |
US20080181903A1 (en) | 2006-12-21 | 2008-07-31 | Pdl Biopharma, Inc. | Conjugate of natriuretic peptide and antibody constant region |
WO2009033707A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
EP2185183B1 (en) | 2007-09-11 | 2016-03-16 | Cardiopep Pharma GmbH | Use of natriuretic peptides for treating angioedema syndromes |
EP2234603A1 (en) | 2007-12-19 | 2010-10-06 | EKR Therapeutics, Inc. | Room temperature stable, lyophilized natriuretic peptide formulations |
WO2009086126A2 (en) | 2007-12-21 | 2009-07-09 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides |
WO2010048308A2 (en) | 2008-10-24 | 2010-04-29 | Deborah Dickey | Natriuretic polypeptides |
US9090695B2 (en) | 2008-12-03 | 2015-07-28 | Morphosys Ag | Antibodies for guanylyl cyclase receptors |
EP2413969A4 (en) | 2009-03-30 | 2012-09-05 | Boehringer Ingelheim Int | FUSION PROTEINS WITH DOG FC ELEMENTS |
US20110065676A1 (en) | 2009-06-24 | 2011-03-17 | Schering Corporation | Combination therapies comprising par1 antagonists with nar agonists |
US20110014180A1 (en) | 2009-07-16 | 2011-01-20 | Masafumi Koide | Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue |
WO2011038066A2 (en) | 2009-09-25 | 2011-03-31 | Alcon Research, Ltd. | Novel npr-b agonists |
CN105732767A (zh) | 2009-09-25 | 2016-07-06 | 夏尔孤儿治疗有限公司 | 新的npr-b激动剂 |
US20130197188A1 (en) | 2010-03-15 | 2013-08-01 | Wolf-Georg Forssmann | Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound |
JP5655147B2 (ja) | 2010-08-20 | 2015-01-14 | セルリアン・ファーマ・インコーポレイテッド | 治療用ペプチド−ポリマーの複合体、粒子、組成物および関連の方法 |
-
2006
- 2006-04-07 PL PL12156696T patent/PL2510942T3/pl unknown
- 2006-04-07 SI SI200632000T patent/SI2510942T1/sl unknown
- 2006-04-07 WO PCT/US2006/013471 patent/WO2006110743A1/en active Application Filing
- 2006-04-07 HU HUE12156696A patent/HUE026231T2/en unknown
- 2006-04-07 US US11/400,696 patent/US7732406B2/en active Active
- 2006-04-07 PT PT121566962T patent/PT2510942E/pt unknown
- 2006-04-07 DK DK12156696.2T patent/DK2510942T3/da active
- 2006-04-07 PT PT06749753T patent/PT1865976E/pt unknown
- 2006-04-07 EP EP12156696.2A patent/EP2510942B1/en active Active
- 2006-04-07 EP EP06749753A patent/EP1865976B1/en active Active
- 2006-04-07 DK DK06749753.7T patent/DK1865976T3/da active
- 2006-04-07 ES ES06749753T patent/ES2392892T3/es active Active
- 2006-04-07 ES ES12156696.2T patent/ES2554713T3/es active Active
- 2006-04-07 PL PL06749753T patent/PL1865976T3/pl unknown
-
2010
- 2010-04-26 US US12/767,395 patent/US8710006B2/en active Active
-
2012
- 2012-07-23 CY CY20121100652T patent/CY1113183T1/el unknown
-
2014
- 2014-03-18 US US14/218,389 patent/US9023794B2/en active Active
-
2015
- 2015-02-26 US US14/632,350 patent/US9358271B2/en active Active
-
2016
- 2016-05-11 US US15/152,220 patent/US20160324931A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2392892T3 (es) | 2012-12-14 |
US8710006B2 (en) | 2014-04-29 |
US20140287999A1 (en) | 2014-09-25 |
HUE026231T2 (en) | 2016-06-28 |
PT2510942E (pt) | 2015-12-28 |
US20150224174A1 (en) | 2015-08-13 |
WO2006110743A1 (en) | 2006-10-19 |
US9358271B2 (en) | 2016-06-07 |
PL1865976T3 (pl) | 2012-11-30 |
US9023794B2 (en) | 2015-05-05 |
US7732406B2 (en) | 2010-06-08 |
EP2510942B1 (en) | 2015-09-02 |
PT1865976E (pt) | 2012-08-03 |
EP1865976A4 (en) | 2010-09-01 |
DK1865976T3 (da) | 2012-07-23 |
EP1865976B1 (en) | 2012-05-23 |
SI2510942T1 (sl) | 2016-01-29 |
US20060264376A1 (en) | 2006-11-23 |
PL2510942T3 (pl) | 2016-02-29 |
ES2554713T3 (es) | 2015-12-22 |
CY1113183T1 (el) | 2016-04-13 |
US20160324931A1 (en) | 2016-11-10 |
EP2510942A1 (en) | 2012-10-17 |
EP1865976A1 (en) | 2007-12-19 |
US20110257099A1 (en) | 2011-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2510942T3 (da) | Anvendelse af natriuretiske peptider til behandling af hjertesvigt | |
Keating et al. | Nesiritide: a review of its use in acute decompensated heart failure | |
Mitrovic et al. | Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial | |
DK2288373T3 (da) | Relaxin til anvendelse i en fremgangsmåde til behandling af dyspnø forbundet med hjerteissuficiens | |
Natali et al. | Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence | |
EP3145534B1 (en) | Relaxin for treating heart failure with preserved ejection fraction | |
US9314507B2 (en) | Methods of treatment of heart failure with natriuretic peptides | |
Zhao et al. | Low-dose nesiritide improves renal function in heart failure patients following acute myocardial infarction | |
AU2014208851B2 (en) | A natriuretic peptide, a diuretic peptide or a vaso dilatory peptide for use in methods of treating cardiovascular indications | |
US10159713B2 (en) | Treatment of type 2 diabetes mellitus patients | |
Bettencourt | Brain natriuretic peptide (nesiritide) in the treatment of heart failure | |
Rigato et al. | Diabetes and the Cardiovascular System | |
James et al. | Congestive Heart Failure: Pharmacological Agents and the Potential of BType Natriuretic Peptide | |
Fabbri et al. | Treatment of patients with heart failure and type 2 diabetes: a review of the literature | |
CA3164959A1 (en) | Treatment of acute heart failure |